CD274 and cancer: The CheckMate017 study showed that in patients with advanced sq-NSCLC cancer, the (median OS: 9.2 months vs 6.0 months), (median PFS: 3.5 months vs 2.8 months) and response rates were significantly better in the nivolumab group than in the docetaxel group, regardless of PD-L1 expression levels (25).